Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.63 |
| ▸ | BCHE | P06276 | 3/20 | 0.59 |
| ▸ | APP | P05067 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14075904 | 0.95 | F2 (0.70) | F2BCHEMAPTMEN1TP53 | |
| SCHEMBL14075918 | 0.85 | APP (0.58) | F2BCHEAPPMEN1KMT2A | |
| SCHEMBL14075899 | 0.85 | BCHE (0.54) | F2BCHEMAPTMEN1TP53 | |
| SCHEMBL7318445 | 0.85 | CXCR4 (0.72) | F2BCHEAPPMAPTMEN1 | |
| SCHEMBL14075895 | 0.84 | TSHR (0.54) | F2BCHEMEN1KMT2A | |
| SCHEMBL15458727 | 0.82 | MAPT (0.73) | F2BCHEAPPMAPTMEN1 | |
| SCHEMBL10055055 | 0.81 | NPC1 (0.54) | F2MEN1KMT2A | |
| SCHEMBL1413125 | 0.81 | FABP1 (0.67) | MEN1KMT2A | |
| Msx-122 SCHEMBL10054965 | 0.81 | CXCR4 (0.61) | MEN1KMT2A | |
| SCHEMBL28475529 | 0.79 | FABP1 (0.64) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779583-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | EMORY UNIVERSITY (US) | 2023-10-10 | — | — | US | disclosed |
| US-11779583-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | EMORY UNIVERSITY (US) | 2023-10-10 | — | — | US | disclosed |
| US-20210401836-A1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | EMORY UNIVERSITY (US) | 2021-12-30 | — | — | US | disclosed |
| US-10632120-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | EMORY UNIVERSITY (US) | 2020-04-28 | — | — | US | disclosed |
| US-20180104243-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | EMORY UNIVERSITY | 2018-04-19 | — | — | US | disclosed |
| US-20180104243-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | EMORY UNIVERSITY | 2018-04-19 | — | — | US | disclosed |
| EP-2776387-B1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | UNIV EMORY (US) | 2017-02-01 | — | — | EP | disclosed |
| US-20160058761-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | METASTATIX, INC. | 2016-03-03 | — | — | US | disclosed |
| US-20160058761-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | METASTATIX, INC. | 2016-03-03 | — | — | US | disclosed |
| US-20160002174-A1 | CXCR4 Antagonists for the Treatment of Medical Disorders | EMORY UNIVERSITY | 2016-01-07 | — | — | US | disclosed |
| WO-2013070660-A1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | EMORY UNIVERSITY (US) | 2013-05-16 | — | — | WO | disclosed |
| US-8114884-B2 | CXCR4 antagonists for the treatment of medical disorders | EMORY UNIVERSITY (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114884-B2 | CXCR4 antagonists for the treatment of medical disorders | EMORY UNIVERSITY (US) | 2012-02-14 | — | — | US | disclosed |
| US-8008312-B2 | CXCR4 antagonists for the treatment of HIV infection | EMORY UNIVERSITY (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008312-B2 | CXCR4 antagonists for the treatment of HIV infection | EMORY UNIVERSITY (US) | 2011-08-30 | — | — | US | disclosed |
| US-20080227799-A1 | CXCR4 Antagonists Including Heteroatoms for the Treatment of Medical Disorders | LIOTTA DENNIS C | 2008-09-18 | — | — | US | disclosed |
| US-20080227799-A1 | CXCR4 Antagonists Including Heteroatoms for the Treatment of Medical Disorders | LIOTTA DENNIS C | 2008-09-18 | — | — | US | disclosed |
| WO-2008008852-A2 | CXCR4 ANTAGONISTS INCLUDING HETEROATOMS FOR THE TREATMENT OF MEDICAL DISORDERS | EMORY UNIVERSITY (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20070054930-A1 | CXCR4 antagonists for the treatment of medical disorders | EMORY UNIVERSITY | 2007-03-08 | — | — | US | disclosed |
| US-20070054930-A1 | CXCR4 antagonists for the treatment of medical disorders | EMORY UNIVERSITY | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401836-A1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | SHBG, ABAT, GLS | F2 867/4885BCHE 188/4885APP 4813/4885 |
| US-10632120-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | SHBG, ABAT, GLS | F2 867/4885BCHE 188/4885APP 4813/4885 |
| US-20080227799-A1 | CXCR4 Antagonists Including Heteroatoms for the Treatment of Medical Disorders | CXCL12, CXCR4, CXCR1 | F2 3871/4885BCHE 4819/4885APP 4065/4885 |
| US-20070054930-A1 | CXCR4 antagonists for the treatment of medical disorders | CXCR4, CXCL12, CXCR1 | F2 3812/4885BCHE 4805/4885APP 3684/4885 |
| US-20160058761-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | SHBG, ABAT, GLS | F2 867/4885BCHE 188/4885APP 4813/4885 |
| US-11779583-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | SHBG, ABAT, GLS | F2 867/4885BCHE 188/4885APP 4813/4885 |
| US-20160002174-A1 | CXCR4 Antagonists for the Treatment of Medical Disorders | CXCR4, CXCL12, CXCR1 | F2 3812/4885BCHE 4805/4885APP 3684/4885 |
| US-20180104243-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | SHBG, ABAT, GLS | F2 867/4885BCHE 188/4885APP 4813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.